James Davies
Ophthalmology · Oceanside, CANPI 1699770511
Payments from drug & device makers
Across 73 payments — averaging $541.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$37K
- Bausch Health US, LLC$1K
- AbbVie$246
- Kala Pharmaceuticals, Inc.$192
- Oyster Point Pharma, Inc.$175
- Bausch & Lomb, A Division Of Bausch Health US, LLC$169
- plus $571 from 13 others
What the payments were for
- Consulting fees$36,58496%
- Speaking & faculty fees$260%
- Food & beverage$1,6174%
- Entertainment$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 9 | $36,900 |
| Bausch Health US, LLC | 2 | $1,285 |
| AbbVie(2 entities) | 13 | $246 |
| Kala Pharmaceuticals, Inc. | 10 | $192 |
| Oyster Point Pharma, Inc. | 5 | $175 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $169 |
| Alcon | 5 | $99 |
| Novartis | 5 | $87 |
| Ivantis, Inc | 4 | $75 |
| Tearlab Corp | 1 | $66 |
| Aerie Pharmaceuticals, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $44 |
| Sight Sciences, Inc. | 2 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $29 |
| Optos, Inc. | 1 | $28 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Beaver-visitec International, Inc. | 1 | $19 |
| Dompe US, Inc. | 1 | $14 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,539 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $12,538 |
| LumiganBimatoprost | 21 | $8,880 |
| Cyclosporine | 12 | $5,666 |
| Latanoprost | 96 | $986 |
| Timolol Maleate | 18 | $852 |
| Prednisolone Acetate | 13 | $452 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $246 | $21,41833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Oceanside
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.